이미프라민염산염

이미프라민염산염 · IMIPRAMINE HCL · g22355 · imidol · ia-pram · imavate · iprogen · tofranil

식별자 및 물리적 특성

CAS No.	113-52-0
분자식	C19H25ClN2
평균 분자량	316.9 g/mol
단동위원소 질량	316.1706265 g/mol
SMILES	CN(C)CCCN1c2ccccc2CCc2ccccc21.Cl
InChIKey	XZZXIYZZBJDEEP-UHFFFAOYSA-N
PubChem CID	8228
ChEMBL	CHEMBL1692
EC No.	204-030-7
DTXSID	DTXSID7040738
현지명	이미프라민염산염

화학 및 물리적 성질

극성 표면적	6.5
수소 결합 공여자 수	1
수소 결합 수용자 수	2
회전 가능 결합 수	4
무거운 원자 수	22
형식 전하	0
복잡도	291
용해도	>47.5 [ug/mL] (The mean of the results at pH 7.4)H2O: 50 mg/mL
Collision Cross Section	165.1 Å² [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]
녹는점	168-1700C
인화점	9℃
저장 조건	2-8°C
물리적 상태	수정 같은
색상	하얀색
pH	4.2~5.2(100g/l,25℃)
용해도	물에 용해됨
Merck	14,4920
InChI	1S/C19H24N2.ClH/c1-20(2)14-7-15-21-18-10-5-3-8-16(18)12-13-17-9-4-6-11-19(17)21/h3-6,8-11H,7,12-15H2,1-2H3
InChIKey	XZZXIYZZBJDEEP-UHFFFAOYSA-N
SMILES	Cl[H].CN(C)CCCN1c2ccccc2CCc3ccccc13
EPA	5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-, monohydrochloride (113-52-0)

화학적 성질

White Solid

안전 및 규제

GHS 분류	WarningH302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 92 reports by companies from 4 notifications to the ECHA C&L Inventory.Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. For more detailed information, please visit ECHA C&L website.
규제 정보	Imipramine hydrochloride: Does not have an individual approval but may be used under an appropriate group standard
기타 안전 정보	IMAP assessments - 5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-, monohydrochloride: Human health tier I assessmentIMAP assessments - 5H-Dibenz[b,f]azepine-5-propanamine, 10,11-dihydro-N,N-dimethyl-, monohydrochloride: Environment tier I assessment
Hazard Classes and Categories	Acute Tox. 4 (100%)
Treatment	Obtain an ECG and immediately initiate cardiac monitoring. Protect the patient's airway, establish an intravenous line and initiate gastric decontamination. A minimum of 6 hours of observation with cardiac monitoring and observation for signs of CNS or respiratory depression, hypotension, cardiac dysrhythmias and/or conduction blocks, and seizures is necessary. If signs of toxicity occur at anytime during this period, extended monitoring is required. (L1712)
노출 경로	Rapidly and well absorbed after oral administration. Bioavailability is approximately 43%. Peak plasma concentrations usually attained 1 - 2 hours following oral administration. Absorption is unaffected by food.
독성 요약	Imipramine works by inhibiting the neuronal reuptake of the neurotransmitters norepinephrine and serotonin. It binds the sodium-dependent serotonin transporter and sodium-dependent norepinephrine transporter preventing or reducing the reuptake of norepinephrine and serotonin by nerve cells. Depression has been linked to a lack of stimulation of the post-synaptic neuron by norepinephrine and serotonin. Slowing the reuptake of these neurotransmitters increases their concentration in the synaptic cleft, which is thought to contribute to relieving symptoms of depression. In addition to acutely inhibiting neurotransmitter re-uptake, imipramine causes down-regulation of cerebral cortical beta-adrenergic receptors and sensitization of post-synaptic serotonergic receptors with chronic use. This leads to enhanced serotonergic transmission.

용도

Imipramine hydrochloride is used as a serotonin uptake inhibitor. It mainly used in the treatment of major depression and enuresis (inability to control urination). It has also been evaluated for use in panic disorder.

일반 설명

Imipramine hydrochloride, 5-[3-(dimethylamino)propyl]-10,11-dihydro-5H-dibenz[b,f]azepine monohydrochloride(Tofranil), is the lead compound of the TCAs. It is also a closerelative of the antipsychotic phenothiazines (replace the10–11 bridge with sulfur, and the compound is the antipsychoticagent promazine). It has weaker D2 postsynaptic blockingactivity than promazine and mainly affects amines (5-HT,NE, and DA) via the transporters. As is typical of dimethylaminocompounds, anticholinergic and sedative (central H1block) effects tend to be marked. The compound per se has a tendency toward a high 5-HT-to-NE uptake block ratio andprobably can be called a serotonin transport inhibitor(SERTI). Metabolic inactivation proceeds mainly by oxidativehydroxylation in the 2-position, followed by conjugationwith glucuronic acid of the conjugate. Urinary excretion predominates(about 75%), but some biliary excretion (up to25%) can occur, probably because of the large nonpolargrouping. Oxidative hydroxylation is not as rapid or completeas that of the more nucleophilic ring phenothiazine antipsychotics;consequently, appreciable N-demethylation occurs,with a buildup of norimipramine (or desimipramine).